These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38060982)

  • 1. Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants.
    Smith RA; Raugi DN; Nixon RS; Seydi M; Margot NA; Callebaut C; Gottlieb GS;
    J Infect Dis; 2024 May; 229(5):1290-1294. PubMed ID: 38060982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No antagonism or cross-resistance and a high barrier to the emergence of resistance
    Diamond TL; Goh SL; Ngo W; Rodriguez S; Xu M; Klein DJ; Grobler JA; Asante-Appiah E
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0033424. PubMed ID: 38864613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus.
    Lee NE; Sutherland RK
    Curr Opin Infect Dis; 2023 Feb; 36(1):15-19. PubMed ID: 36753704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenacapavir: a first-in-class HIV-1 capsid inhibitor.
    Dvory-Sobol H; Shaik N; Callebaut C; Rhee MS
    Curr Opin HIV AIDS; 2022 Jan; 17(1):15-21. PubMed ID: 34871187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
    Segal-Maurer S; DeJesus E; Stellbrink HJ; Castagna A; Richmond GJ; Sinclair GI; Siripassorn K; Ruane PJ; Berhe M; Wang H; Margot NA; Dvory-Sobol H; Hyland RH; Brainard DM; Rhee MS; Baeten JM; Molina JM;
    N Engl J Med; 2022 May; 386(19):1793-1803. PubMed ID: 35544387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.
    Margot N; Vanderveen L; Naik V; Ram R; Parvangada PC; Martin R; Rhee M; Callebaut C
    J Antimicrob Chemother; 2022 Mar; 77(4):989-995. PubMed ID: 35028668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.
    Wu VH; Smith RA; Masoum S; Raugi DN; Ba S; Seydi M; Grobler JA; Gottlieb GS;
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.
    Margot N; Ram R; Rhee M; Callebaut C
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.
    Smith RA; Raugi DN; Wu VH; Leong SS; Parker KM; Oakes MK; Sow PS; Ba S; Seydi M; Gottlieb GS;
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7437-46. PubMed ID: 26392486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case Report of Lenacapavir Use in a Patient with Multidrug-Resistant HIV: The First Experience in Asia.
    Lee Y; Lee KH; Lee JA; Ahn SM; Han M; Choi JY
    Yonsei Med J; 2024 Oct; 65(10):619-622. PubMed ID: 39313453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral drug resistance and resistance testing.
    Gallant JE
    Top HIV Med; 2005 Dec-2006 Jan; 13(5):138-42. PubMed ID: 16377851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
    Ptak RG; Gentry BG; Hartman TL; Watson KM; Osterling MC; Buckheit RW; Townsend LB; Drach JC
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1512-9. PubMed ID: 20086149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV.
    Prather C; Lee A; Yen C
    Am J Health Syst Pharm; 2023 Dec; 80(24):1774-1780. PubMed ID: 37767713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use.
    Balzarini J; François KO; Van Laethem K; Hoorelbeke B; Renders M; Auwerx J; Liekens S; Oki T; Igarashi Y; Schols D
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1425-35. PubMed ID: 20047920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya.
    Makwaga O; Adhiambo M; Mulama DH; Muoma J; Adungo F; Wanjiku H; Ongaya A; Maitha GM; Mwau M
    Pan Afr Med J; 2020; 37():311. PubMed ID: 33654530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).
    Shimura K; Kodama E; Sakagami Y; Matsuzaki Y; Watanabe W; Yamataka K; Watanabe Y; Ohata Y; Doi S; Sato M; Kano M; Ikeda S; Matsuoka M
    J Virol; 2008 Jan; 82(2):764-74. PubMed ID: 17977962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.